18f fp-r01-mg-f2

Small moleculeexperimentalImaging agent

Clinical trial activity

2 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Jan 1, 2016 (NCT02683824)

Timeline

2010s

  1. Jan 1, 2017

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetRadiopharmaceutical

    radiopharmaceutical

Chemistry & pharmacology

Imaging
18-fluorine

Oral

No

Parenteral

No

Topical

No

Also known as

  • 18f fp-r01-mg-f2

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03183570Early Phase 1 (Phase 1)Jun 25, 2017Pliant Therapeutics, Stanford University
NCT02683824N/AJan 1, 2016National Cancer Institute (NCI), Stanford University
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Stanford UniversityAcademic/Hospital2222016
National Cancer Institute (NCI)Government1012016
Pliant TherapeuticsFor profit1012017
3 organizations
Page 1 / 1